Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 1.34 Vs. IBES Estimate USD 1.09
08/11/2024 11:51
Nov 08 (Reuters) - ANI Pharmaceuticals Q3 revenue USD 148.332 million vs. IBES estimate USD 144.4 million. * outlook FY adjusted EPS USD 4.9-5.05 * outlook FY adjusted EBITDA USD 149-153 million
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary